HEK293-CCR8 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Stable (KO/Expressing) Cells |
| Tissue Type |
Transformed cell lines |
| Organism |
Human |
| Donor History |
Transformed/immortalized; non-tumorigenic (HEK293 background) |
| Growth Properties |
Monolayer ,adherent |
| Growth Conditions |
Culture medium: RPMI 1640 ,w: 2.0 mM stable Glutamine ,w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS ,1 mM sodium pyruvate ,10 mM HEPES ,1% NEAA. Add Geneticin (G418-Sulfat) to achieve a final concentration of 1 mg/mL. Dissociation reagent: Trypsin-EDTA. Seeding density: 2 to 4 x 10⁴ cells/cm². Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
Disclaimer: The prices displayed for cell lines are exclusively for academic/not-for-profit customers. For commercial entitites the price is approximately €6,250. If you represent a commercial entity or are unsure which category applies, please
contact us.
The HEK293-CCR8 cell line is a stable recombinant HEK293 cell line engineered to express the CCR8 receptor at a medium-high level, approximately 22,000 molecules per cell. This cell line was developed using inscreenex’s landing pad technology, ensuring precise and reproducible integration of the CCR8 gene at a specific, pre-validated genomic locus. CCR8, also known as CHEMR1 or CDw198, is a G protein-coupled receptor (GPCR) that is predominantly expressed on regulatory T cells (Tregs). It plays a crucial role in the suppression of immune responses within the tumor microenvironment, aiding tumor cells in evading immune detection. Due to its role in maintaining an immunosuppressive environment, CCR8 has become a promising target for novel cancer immunotherapies aimed at enhancing anti-tumor immunity by reducing Treg-mediated suppression.The expression of CCR8 in this cell line was confirmed using flow cytometry with a target-specific antibody, ensuring consistent and reliable receptor density across the cell population.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

